歌禮制藥(01672.HK)逆市續漲17%重越5元關 旗下新冠口服藥或提前申請臨牀試驗
歌禮制藥-B(01672.HK)先後公佈實體瘤藥美國臨牀試驗申請獲批及新冠口服藥或提前申請臨牀試驗。該股繼昨天回升10%,今天進一步突破20天線(4.47元),最高見5.17元,現報5.03元,續漲17%,成交進一步倍增至2,560萬股。
歌禮繼昨天公佈旗下用於治療晚期實體瘤的口服PD-L1小分子抑制劑ASC61美國臨牀試驗申請獲批,首例美國患者料將於2022年上半年完成給藥後,今天再公佈旗下口服雙前藥ASC10及其抗病毒核(甘)類似物ASC10-A,在抑制包括Omicron在內的多種新冠病毒變異病毒株體內和體外積極數據,指通過採用雙前藥策略,ASC10在Caco-2細胞(人結直腸腺癌細胞)中的滲透性和在猴子中的口服生物利用度分別是莫努匹韋(Molnupiravir)的3.2倍和2.3倍。基於猴子和人之間的藥物暴露量關聯關係,預計口服雙前藥ASC10在患者中具有更高的藥物暴露量,ASC10在臨牀試驗中對新冠病毒的療效可能比莫努匹韋(Molnupiravir)更好。因此,向中國及美國等國家提交臨牀試驗申請時間可能早於公司原先預期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.